Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model.

Zhao, Hengli; Wei, Yilin; He, Kun; Zhao, Xiaoyu; Mu, Hongli; Wen, Qing

Zhao, Hengli; Wei, Yilin; He, Kun; Zhao, Xiaoyu; Mu, Hongli; Wen, Qing.

Afiliação

Zhao H; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China.
Wei Y; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China.
He K; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China.
Zhao X; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China.
Mu H; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China.
Wen Q; Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China. Electronic address: wenq0619@126.com.

Eur J Pharm Sci ; 179: 106298, 2022 Dec 01.

Article em En | MEDLINE | ID: mdl-36162752

Assuntos

Diabetes Mellitus Tipo 2; Hepatopatias; Humanos; Diabetes Mellitus Tipo 2/complicações; Diabetes Mellitus Tipo 2/tratamento farmacológico; Cirrose Hepática/tratamento farmacológico; Área Sob a Curva; Modelos Biológicos

Palavras-chave

Janagliflozin; Liver cirrhosis; PBPK model; Renal impairment; T2DM

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hepatopatias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google